Medicenna Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting

Rhea-AI Summary

Medicenna Therapeutics Corp. (NASDAQ: MDNA) announced the acceptance of two abstracts for poster presentations at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, scheduled from November 8 – 12, 2022, in Boston, MA.

The abstracts will be published on November 7, 2022, and detail studies on MDNA11, a long-acting IL-2 agonist. The first presentation covers pharmacokinetics and pharmacodynamics, while the second focuses on interim safety and anti-tumor activity.

TORONTO and HOUSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced the acceptance of two abstracts for poster presentations at the Society for Immunotherapy of Cancer (SITC) 37^th Annual Meeting, which is taking place both virtually and in-person at the Boston Convention and Exhibition Center in Boston, MA, from November 8 – 12, 2022.

Both abstracts will be published by SITC at 8:00 a.m. ET on November 7, 2022. Additional details on the abstracts and corresponding poster presentations are shown below.

Title: Pharmacokinetic and Pharmacodynamic Profile of a First-in-Human Study with MDNA11, an Engineered Long-Acting ‘Beta-only’ IL2 Agonist
Abstract Number: 743
Poster Presentation Date and Time: November 10, 2022, from 9:00 a.m. – 9:00 p.m. ET
Poster Session Location: Boston Convention and Exhibition Center, Hall C

Title: Interim Single-agent Safety and Anti-tumor Activity from Dose Escalation Phase of ABILITY Study on MDNA11, a Long-acting Beta-only IL-2 Agonist
Abstract Number: 744
Poster Presentation Date and Time: November 11, 2022, from 9:00 a.m. – 8:30 p.m. ET
Poster Session Location: Boston Convention and Exhibition Center, Hall C

About Medicenna
Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines. Medicenna's long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity thereby preferentially stimulating cancer killing effector T cells and NK cells. Medicenna’s early-stage BiSKITs™ program, (Bifunctional SuperKine ImmunoTherapies) is designed to enhance the ability of Superkines to treat immunologically “cold” tumors. Medicenna's IL-4 Empowered Superkine, MDNA55, has been studied in 5 clinical trials including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively.

 

FAQ

What is MDNA11 and its significance for Medicenna's research?

MDNA11 is a long-acting IL-2 agonist developed by Medicenna, designed to preferentially stimulate cancer-killing effector T cells and NK cells, which may enhance anti-tumor responses.

When will the SITC 37th Annual Meeting take place?

The SITC 37th Annual Meeting will occur from November 8 – 12, 2022, in Boston, MA.

What abstracts will Medicenna present at the SITC meeting?

Medicenna will present two abstracts related to MDNA11, focusing on its pharmacokinetic and pharmacodynamic profile and interim safety and anti-tumor activity.

When will the abstracts be published by SITC?

The abstracts will be published by SITC at 8:00 a.m. ET on November 7, 2022.

What are the presentation dates for Medicenna's abstracts?

The first abstract will be presented on November 10, 2022, and the second on November 11, 2022.